When do biologic drug patents expire and when will biosimilars launch?

United States Patent 8,337,811: What the Claims Actually Cover and Where the Landscape Breaks

US Patent 8,337,811 is drafted to claim a specific nanoparticle architecture used to deliver an erythropoiesis-stimulating pharmacology payload for anemia. The independent claim (claim 1) ties together four technical pillars that define scope and also concentrate risk to validity and design-around: (i) a chitosan-dominated positively charged shell and core, (ii) a defined negatively charged substrate within/associated with that chitosan construct, (iii) one or more loaded bioactive agents that stimulate red blood cell production, and (iv) optional “zero-charge compound” language.

From a patent-coverage standpoint, the claim language is broad on the “bioactive agent” identity (it sweeps multiple ERYTHROPOIESIS and HIF-related modalities), but it is narrow on the nanoparticle’s charge architecture (positively charged chitosan shell/core plus a negatively charged substrate as specified in dependent claim 15). That combination creates a landscape in which many “erythropoietin delivery nanoparticles” may still fall outside infringement if they do not implement the same chitosan-positive shell/core plus specific negatively charged substrate construct.

What Does Claim 1 Actually Require? (Independent Claim Construction)

Claim 1 requires all of the following elements:

A pharmaceutical composition of nanoparticles for treatment of anemia in an animal subject.
Nanoparticles have a shell portion “dominated by positively charged chitosan.”
Nanoparticles have a core portion that “consists of said positively charged chitosan.”
A negatively charged substrate is included (as part of the construct described in claim 1).
At least one bioactive agent is loaded in the nanoparticles.
Optional “zero-charge compound” is permitted.
The bioactive agent “is an agent that stimulates red blood cell production” in the subject.

Why this claim structure matters

The claim is not just “chitosan nanoparticles.” It is charge-architected: positive chitosan dominates shell and core, while a separately recited negatively charged substrate is present.
The optional “zero-charge compound” expands coverage but does not remove the need for the positive chitosan shell/core and negatively charged substrate.
“An agent that stimulates red blood cell production” is a functional definition that invites wide interpretation, which increases infringement exposure for a platform that delivers erythropoiesis stimulators (including ERYTHROPOIESIS direct agents and indirectly acting HIF stabilizers).

What Specific Dependent Claims Lock In (and Where They Narrow Scope)

How far do the dependent claims narrow the chitosan definition? (Claim 2)

Claim 2 states chitosan can be:

N-trimethyl chitosan
EDTA-chitosan
low molecular weight chitosan
PEGylated chitosan (PEG-chitosan)
mono-N-carboxymethyl chitosan
N-palmitoyl chitosan (NPCS)
“chitosan derivatives” and combinations

Practical read: This broadens the claim to multiple chitosan chemistries while still requiring the chitosan to be positively charged in the overall nanoparticle architecture of claim 1.

Which pharmacologies are explicitly swept in? (Claims 3, 17, 18, 19, 20)

Claim 3: bioactive agent is erythropoietin or an erythropoiesis-stimulating agent.
Claim 17: explicitly lists:
- Epoetin alfa (Procrit, Epogen)
- Epoetin beta (NeoRecormon)
- Darbepoetin alfa (Aranesp)
- Methoxy polyethylene glycol-epoetin beta (Mircera)
Claim 18: erythropoietin-mimetic peptide 1 (EMP-1) or peginesatide (claim 19).
Claim 20: an agent for enhancing HIF stabilization

Practical read: The set includes both classical biologics (epoetins, darbepoetin) and smaller-molecule or peptide/HIF-axis entries. That increases platform scope but also raises prior-art pressure because the “payload list” tracks known anemia therapeutics and known HIF stabilization approaches.

How do formulation claims expand packaging and administration routes? (Claims 4-7, 9, 14)

Freeze-dried nanoparticles (claim 4) with powder form.
Freeze-dried with a cryoprotectant (claims 5-6), cryoprotectants include:
- trehalose
- mannitol
- DMSO
- ethylene glycol
- glycol
- 2-methyl-2,4-pentanediol
- propylene
- sucrose
- hexan-1,2,3,4,5,6-hexol
Encapsulated in a capsule (claim 7).
Capsule materials:
- methyl cellulose with explicit HPMC/CMC/HEMC variants (claim 8)
- gelatin (claim 13)
Enteric coating:
- capsule enteric coating (claim 9)
- nanoparticles treated with an enteric coating (claim 14)

Practical read: These claims extend the formulation vector beyond simple injectable nanoparticle suspension toward oral or gastro-resistant administration. That is material because many competing platforms are injectable and avoid enteric or capsule packaging.

Which “accessory” excipient logic is claimed for absorption enhancement? (Claims 10-16)

Claim 10 includes a long list of pharmaceutical carrier components. Claim 11: capsule further comprises “at least one absorption enhancer.” Claim 12: absorption enhancers include:

bile salts
surfactants
medium-chain fatty acids
phosphate esters
chitosan and chitosan derivatives

Claim 16: “zero-charge compound is an absorption enhancer.”

Practical read: The patent uses “absorption enhancer” language as a handle that can capture common oral delivery excipients. The combination of enteric coating + capsule polymer selection + absorption enhancers creates a plausible broader infringement surface against oral nanoparticle formulations if they also keep the charge architecture of claim 1.

What negative substrate types are explicitly claimed? (Claim 15)

Claim 15: negatively charged substrate is:

PGA-complexone conjugate
γ-PGA
α-PGA
derivatives of PGA
salts of PGA

Practical read: This is the most important narrowing. If a competitor uses a different negative polyanion (e.g., alginate, hyaluronate, heparin, sulfate-bearing polymers, DNA/RNA scaffolds), it may avoid claim 15 even if it uses positively charged chitosan elsewhere. However, because claim 1 itself requires a “negatively charged substrate” generically, a competitor must still address whether any negative substrate they use is argued to fall under the generic element, and whether the specification ties that generic element to PGA-like materials.

High-Value Claim Map: “What Would Infringe” vs “What Likely Avoids”

Element family	What must be present (based on claims)	Likely infringement risk when present	Common design-around targets
Nanoparticle charge architecture	Positively charged chitosan shell dominates + core consists of positively charged chitosan + a negatively charged substrate	Higher	Use different polymer architecture (no “shell dominated by chitosan”); switch negative substrate away from PGA family; keep chitosan but change its role/placement
Payload	Erythropoiesis-stimulating agents, including epoetins/darbepoetin/peginesatide/HIF stabilization	Higher	Use different therapeutic payloads not argued to stimulate red blood cells (hard because anemia treatment space overlaps functionally); change route or avoid nanoparticle loading architecture
Form	Freeze-drying, cryoprotectants, powder form	Medium (if competitor is suspension/injectable)	Avoid freeze-dried format; avoid specified cryoprotectant classes
Oral delivery stack	capsule (methyl cellulose or gelatin), enteric coating, absorption enhancer; “zero-charge compound” as absorption enhancer	Higher if oral	Avoid capsule enteric combination; avoid absorption enhancers as “zero-charge” concept; use different dosage forms
Negative substrate identity	PGA complexone conjugate / α-PGA / γ-PGA / derivatives / salts (claim 15)	Very high if PGA used	Substitute another polyanion negative substrate not described as PGA derivatives

Patent Landscape: Where the Business Wins and Where It Gets Cornered

1) The claim’s payload list aligns with established anemia therapeutics

Claim 17’s explicit epoetin/darbepoetin/methoxy-PEG epoetin naming increases the likelihood that infringers in this space are aware of the core payload. That increases licensing pressure for platforms that deliver these biologics via chitosan-based nanoparticles.

Business implication: If an R&D program aims at oral or protected delivery of epoetins/darbepoetin, it faces a higher litigation surface because the patent names those drugs directly (claim 17).

2) The charge architecture narrows the field more than the payload does

While the payload is broad, the architecture is specific. Competitors can reduce risk by:

using different cationic carriers (or using chitosan but not as a positively charged shell-dominant structure),
replacing the PGA family with another negatively charged substrate,
changing the “core portion consists of positively charged chitosan” element so that the core is not pure positively charged chitosan.

Business implication: The strongest freedom-to-operate lever is the negatively charged substrate choice and how chitosan is structurally positioned (shell-core dominance and core composition).

3) Oral delivery add-ons create exposure even if nanoparticle core is similar

The capsule and enteric coating dependent claims (claims 7-9 and 14) plus absorption enhancer language (claims 11-12 and 16) can expand infringement coverage for oral formulations.

Business implication: A program can avoid nanoparticle claim elements yet still land in the dependent claims if its dosage form matches the capsule/enteric/excipient bundle and if it cannot separate the “zero-charge compound” concept from absorption enhancers.

4) Freeze-drying and cryoprotectants expand practical infringement scenarios

Freeze-dried powder formulations are common for long shelf-life. Claim 5-6 lists a relatively broad cryoprotectant set. If a competitor uses common lyoprotectants like trehalose or mannitol, that narrows design-around options.

Business implication: If a competitor targets commercial manufacturability via freeze-drying, they may inadvertently align with these dependent claims, leaving only the charge architecture and negative substrate as true escape paths.

Critical Claim-Strength Assessment: Validity and Enforceability Pressure Points

Functional payload definition can broaden interpretation

Claim 1 defines “bioactive agent” functionally as stimulating red blood cell production. That can pull in agents not listed in the dependent claims, depending on how the patent’s specification supports the functional scope.

Enforceability effect: Broader functional language increases infringement capture risk but also attracts prior-art overlap because multiple anemia drugs share the same functional endpoints.

PGA negative substrate specificity is a validity-and-infringement anchor

Claim 15 provides concrete negative substrate identity (PGA, α/γ, derivatives). This both:

helps distinguish against prior art that uses different polyanions, and
creates a design-around channel for those using different negative substrates.

Enforceability effect: A court’s claim construction may turn on whether “negatively charged substrate” in claim 1 is tied to PGA in the specification or remains generic. If it is generic, claim 15 becomes less isolating; if it is specification-limited, then claim 15 becomes the real boundary.

Charge architecture language may be litigated as structural vs outcome

Phrases like “shell portion dominated by positively charged chitosan” and “core portion consists of said positively charged chitosan” are structural but contain a degree of interpretive leverage (“dominated”). Competitors could challenge whether their measured zeta potential distributions and composition profiles satisfy the “dominated” and “consists of” thresholds.

Enforceability effect: Expect fights over characterization data (composition, charge distribution), not only the general concept of chitosan nanoparticles.

Actionable Landscape Conclusions for R&D and Licensing

Where to focus for freedom-to-operate

Negatively charged substrate identity and role: alignments with α-PGA/γ-PGA/PGA derivatives raise risk; alternatives reduce it but do not fully eliminate claim 1 risk if “negatively charged substrate” is construed broadly.
Chitosan structural placement and composition purity: ensure whether the core “consists of positively charged chitosan” is not mirrored by competitor designs.
Oral formulation stack: capsule type (methyl cellulose vs gelatin), enteric coating use, and absorption enhancer selection can trigger dependent coverage.

Where licensing leverage is highest

Programs delivering epoetins/darbepoetin/mircera via chitosan-positive nanoparticle shells/cores and using PGA family polyanions for the negative component are the most licensing-sensitive.
Oral delivery programs using enteric-coated capsules and common excipients that function as absorption enhancers face higher dependent-claim exposure.

Key Takeaways

US 8,337,811 centers on a charge-architected chitosan nanoparticle system for anemia therapy, with PGA-family negatively charged substrates explicitly claimed in dependent claim 15.
The payload scope is broad (erythropoiesis stimulators, including epoetins, peginesatide/EMP-1, and HIF stabilization) but the strongest technical boundary is the nanoparticle structural charge architecture.
Oral delivery implementations (capsules, enteric coatings, absorption enhancers) and freeze-dried lyophilization add dependent-claim risk for commercial-formulation pathways.
The highest freedom-to-operate lever is likely changing the negative substrate system and ensuring the chitosan shell/core structural arrangement does not match “dominated shell” and “core consists of positively charged chitosan.”

FAQs

Does US 8,337,811 claim any nanoparticle that delivers an erythropoietic drug?
No. Claim 1 requires a specific architecture: positively charged chitosan dominating the shell and composing the core, plus a negatively charged substrate, with a loaded erythropoiesis-stimulating bioactive agent.
How important is the negatively charged substrate in this patent?
It is central. Claim 15 explicitly limits it to PGA family materials (α/γ-PGA, derivatives, salts), creating a likely design-around if a competitor uses a different negative polyanion system.
Are enteric-coated oral dosage forms within the claim coverage?
Yes. The patent includes dependent coverage for capsules (methyl cellulose or gelatin) with enteric coating, and also for enteric coating treated nanoparticles.
What payloads are explicitly named?
The claims explicitly name epoetin alfa, epoetin beta, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta, plus erythropoietin-mimetic and HIF stabilization agents (through dependent claims).
Do freeze-dried and lyoprotectant choices matter for infringement?
They can. Claims 4-6 cover freeze-dried powder form and list multiple cryoprotectants that are widely used in lyophilization.

References

[1] United States Patent and Trademark Office. US Patent 8,337,811 (as provided in the user prompt claim text).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	June 01, 1989	8,337,811	2032-03-12
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		8,337,811	2032-03-12
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		8,337,811	2032-03-12
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	September 17, 2001	8,337,811	2032-03-12
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	July 19, 2002	8,337,811	2032-03-12
Amgen Inc.	ARANESP	darbepoetin alpha	Injection	103951	December 17, 2002	8,337,811	2032-03-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 8,337,811

Summary for Patent: 8,337,811